24-Valent Pneumococcal Polysaccharide Conjugate Vaccine(Vaxcyte)

The growth of the pneumonia market is expected to be primarily driven by an expanding patient population and advancements in diagnostic methods. Additionally, the expected launch of emerging therapies such as Tosatoxumab (AR-301) (Aridis Pharmaceuticals), AON-D21 (Aptarion Biotech), Trimodulin (BT588) (Biotest AG), VAX-24 and VAX-31 (Vaxcyte, Inc.), PCV24 (CanSinoBIO), IVT PCV-25 (Inventprise), and others will further propel the market forward.. 肺炎市场的增长预计将主要由患者群体的扩大和诊断方法的进步所驱动。此外，Tosatoxumab（AR-301）（Aridis Pharmaceuticals）、AON-D21（Aptarion Biotech）、Trimodulin（BT588）（Biotest AG）、VAX-24 和 VAX-31（Vaxcyte, Inc.）、PCV24（康希诺生物）、IVT PCV-25（Inventprise）等新兴疗法的预期上市将进一步推动市场发展。LAS VEGAS 拉斯维加斯, ，June 8, 2026 2026年6月8日/PRNewswire/ -- Recently published Pneumonia Market Insights report includes a comprehensive understanding of current treatment practices, pneumonia emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].. /美通社/ -- 最近发布的《肺炎市场洞察》报告全面解析了当前的治疗实践、肺炎新兴药物、各疗法的市场份额，以及2022年至2036年的当前市场规模和预测市场规模，并按主要市场（美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本）进行了细分。Pneumonia Market Summary 肺炎市场概要The total pneumonia treatment market size is expected to grow positively by 2036 in the leading markets. 到2036年，主要市场的肺炎治疗总市场规模预计将实现正增长。The United States accounted for the largest pneumonia treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. 与欧盟四国（德国、法国、意大利和西班牙）、英国和日本等其他主要市场相比，美国在2025年占据了最大的肺炎治疗市场规模。In the United States, the annual incidence of community-acquired pneumonia (CAP) is estimated at approximately 在美国，社区获得性肺炎（CAP）的年发病率估计约为24.8 cases per 10,000 每万人24.8例adults, with rates increasing significantly with advancing age. 成年人，且患病率随年龄增长而显著上升。Leading pneumonia companies, such as 领先的肺炎相关企业，例如Aridis Pharmaceuticals, Aptarion Biotech, Biotest AG, Vaxcyte, Inc., CanSinoBIO, Inventprise, BioVersys, Aridis Pharmaceuticals，Aptarion Biotech，Biotest AG，Vaxcyte, Inc.，康希诺生物，Inventprise，BioVersys，and others, are developing new pneumonia treatment drugs that can be available in the pneumonia market in the coming years. 以及其他公司，正在开发新的肺炎治疗药物，这些药物有望在未来几年内上市。The promising pneumonia therapies in clinical trials include 临床试验中颇具前景的肺炎疗法包括Tosatoxumab (AR-301), AON-D21, Trimodulin (BT588), VAX-24, VAX-31, PCV24, IVT PCV-25, BV100, 托萨特珠单抗（AR-301）、AON-D21、曲莫杜林（BT588）、VAX-24、VAX-31、PCV24、IVT PCV-25、BV100，and others. 以及其他。Discover what is the global pneumonia therapeutics market size @ 了解全球肺炎治疗药物市场规模 @https://www.delveinsight.com/report-store/pneumonia-pneumococcal-market https://www.delveinsight.com/report-store/pneumonia-pneumococcal-marketKey Factors Driving the Growth of the Pneumonia Market 推动肺炎市场增长的关键因素Rising Pneumonia Incident Cases: 肺炎病例数上升：As per the analysis, the total incident cases of pneumonia are expected to increase during the forecast period (2026–2036). This anticipated rise is primarily driven by demographic shifts, particularly the aging population, as older adults are at significantly higher risk of developing pneumonia due to declining immune function and a greater prevalence of chronic comorbid conditions.. 根据分析，预计在预测期（2026–2036年）内，肺炎的总发病病例数将增加。这一预期增长主要由人口结构变化驱动，尤其是人口老龄化，因为老年人由于免疫功能下降以及慢性共病患病率较高，罹患肺炎的风险显著增加。Growing Geriatric Population: 老年人口不断增长：The expanding aging population significantly contributes to the growth of the pneumonia market. Older adults are more susceptible to respiratory infections due to weakened immune systems and age-related comorbidities. 不断扩大的老龄化人口显著推动了肺炎市场的增长。由于免疫系统减弱以及与年龄相关的合并症，老年人更容易受到呼吸道感染的影响。Increasing Burden of Chronic Diseases: 慢性疾病的负担日益加重：Chronic health conditions such as chronic obstructive pulmonary disease (COPD), asthma, diabetes, and cardiovascular diseases increase susceptibility to pneumonia. The rising prevalence of these conditions worldwide is leading to a higher incidence of pneumonia-related complications, thereby expanding the demand for effective treatment options and supportive therapies.. 慢性阻塞性肺疾病（COPD）、哮喘、糖尿病和心血管疾病等慢性健康状况会增加患肺炎的易感性。这些状况在全球范围内的患病率不断上升，导致肺炎相关并发症的发生率增高，从而扩大了对有效治疗方案和支持性疗法的需求。Advancements in Diagnostics and Treatment Technologies: 诊断与治疗技术的进步：Technological innovations in molecular diagnostics, PCR-based testing, and rapid point-of-care diagnostics are enabling earlier and more accurate detection of pneumonia pathogens. These advances improve treatment outcomes and support the development of targeted therapies, contributing significantly to market growth.. 分子诊断、基于PCR的检测以及快速即时检测领域的技术创新，使得对肺炎病原体的检测更加早期和准确。这些进步改善了治疗结果，并支持靶向疗法的发展，从而显著推动了市场增长。Increasing Adoption of Vaccination Programs: 疫苗接种计划的日益普及：Government initiatives and global immunization campaigns promoting pneumococcal and influenza vaccination are boosting demand for pneumonia prevention solutions. 政府倡议和全球免疫运动正在推动肺炎球菌和流感疫苗接种，从而提升了对肺炎预防解决方案的需求。Launch of Emerging Pneumonia Drugs: 新兴肺炎药物的上市：The dynamics of the pneumonia market are expected to change in the coming years due to the launch of emerging therapies such as 由于新兴疗法（如）的推出，预计肺炎市场动态将在未来几年发生变化Tosatoxumab (AR-301) 托沙妥昔单抗（AR-301）(Aridis Pharmaceuticals), （Aridis Pharmaceuticals）AON-D21 AON-D21(Aptarion Biotech), （Aptarion Biotech），Trimodulin (BT588) Trimodulin (BT588)(Biotest AG), （Biotest AG），VAX-24 and VAX-31 VAX-24 和 VAX-31(Vaxcyte, Inc.), （Vaxcyte 公司）PCV24 PCV24(CanSinoBIO), （康希诺生物）IVT PCV-25 IVT PCV-25(Inventprise), (Inventprise)BV100 BV100(BioVersys), and others. (BioVersys) 等。According to Ramandeep Singh, Senior Consultant of Forecasting and Analytics at DelveInsight, the pneumonia market in the 7MM is expected to witness steady growth during the forecast period (2026–2036), driven by the rising incidence of community- and hospital-acquired pneumonia, increasing antimicrobial resistance, improved diagnostic capabilities, and the introduction of novel targeted therapies and vaccines.. 根据DelveInsight预测与分析高级顾问Ramandeep Singh的观点，在预测期（2026–2036年）内，七大主要市场（7MM）的肺炎市场预计将实现稳步增长，这一增长得益于社区获得性肺炎和医院获得性肺炎发病率的上升、抗菌药物耐药性的增加、诊断能力的提升，以及新型靶向疗法和疫苗的推出。Pneumonia Market Analysis 肺炎市场分析The treatment of pneumonia is determined by its underlying cause, the severity of the infection, and individual patient characteristics. 肺炎的治疗取决于其根本病因、感染的严重程度以及患者的个体特征。Bacterial pneumonia is generally managed with suitable antibiotic therapy, whereas viral pneumonia is often treated with supportive care and, in certain situations, antiviral agents. 细菌性肺炎通常采用合适的抗生素治疗，而病毒性肺炎则常采取支持性护理，并在特定情况下使用抗病毒药物。Supportive measures typically include adequate rest, proper hydration, and hospitalization in severe cases. 支持性措施通常包括充分休息、适当补水，以及在重症情况下住院治疗。Preventive strategies, particularly vaccination against pathogens like Streptococcus pneumoniae and influenza viruses, are also essential in reducing the risk of specific forms of pneumonia. 预防策略，特别是针对肺炎链球菌和流感病毒等病原体的疫苗接种，对于降低特定类型肺炎的风险也至关重要。Several therapies approved by the U.S. Food and Drug Administration are available for pneumonia treatment, including 美国食品药品监督管理局批准的多种肺炎治疗疗法可供选择，包括XACDURO (sulbactam + durlobactam) XACDURO（舒巴坦 + 杜洛巴坦）and 和ZEVTERA (ceftobiprole medocaril) ZEVTERA（头孢比普罗酯）, among others. ，以及其他。In addition, emerging pipeline candidates such as 此外，新兴的管线候选药物如Tosatoxumab (AR-301) 托萨妥昔单抗（AR-301）(Aridis Pharmaceuticals), （Aridis Pharmaceuticals）AON-D21 AON-D21(Aptarion Biotech), （Aptarion Biotech）Trimodulin (BT588) 特里莫杜林（BT588）(Biotest AG), （Biotest AG）VAX-24 and VAX-31 VAX-24 和 VAX-31(Vaxcyte, Inc.), （Vaxcyte, Inc.）PCV24 PCV24(CanSinoBIO), （康希诺生物）IVT PCV-25 IVT PCV-25(Inventprise), (Inventprise),BV100 BV100(BioVersys), and others are progressing through development and are expected to further reshape the pneumonia treatment landscape through innovative targeted mechanisms. （BioVersys）等公司正在推进研发进程，预计将通过创新的靶向机制进一步重塑肺炎治疗格局。Pneumonia Competitive Landscape 肺炎竞争格局Some of the pneumonia drugs under development include 正在开发的一些肺炎药物包括Tosatoxumab (AR-301) 托沙妥昔单抗（AR-301）(Aridis Pharmaceuticals), （Aridis Pharmaceuticals）AON-D21 AON-D21(Aptarion Biotech), （Aptarion Biotech）Trimodulin (BT588) Trimodulin (BT588)(Biotest AG), （Biotest AG）VAX-24 and VAX-31 VAX-24 和 VAX-31(Vaxcyte, Inc.), （Vaxcyte, Inc.）PCV24 PCV24(CanSinoBIO), （康希诺生物）IVT PCV-25 IVT PCV-25(Inventprise), （Inventprise）BV100 BV100(BioVersys), and others. （BioVersys）以及其他公司。Aridis Pharmaceuticals' AR-301 (tosatoxumab) Aridis Pharmaceuticals 公司的 AR-301（托沙妥珠单抗）is a fully human IgG1 monoclonal antibody developed to specifically bind and neutralize the alpha-toxin produced by 是一种全人源IgG1单克隆抗体，旨在特异性结合并中和由Staphylococcus aureus 金黄色葡萄球菌, a major virulence factor present in both methicillin-resistant (MRSA) and methicillin-sensitive (MSSA) strains. By inhibiting this toxin, AR-301 helps limit toxin-induced damage to host tissues while maintaining immune cell functionality. Since its mechanism of action does not depend on the bacterium's antibiotic resistance status, it can potentially be effective against infections caused by both MRSA and MSSA strains.. ，这是一种存在于耐甲氧西林金黄色葡萄球菌（MRSA）和甲氧西林敏感金黄色葡萄球菌（MSSA）菌株中的主要毒力因子。通过抑制这种毒素，AR-301 有助于限制毒素对宿主组织造成的损伤，同时保持免疫细胞的功能。由于其作用机制不依赖于细菌的抗生素耐药状态，因此它有可能对由 MRSA 和 MSSA 菌株引起的感染均有效。In July 2023, the US FDA granted Qualified Infectious Disease Product (QIDP) designation to tosatoxumab (AR-301), supporting its accelerated clinical development as an adjunctive treatment for 2023年7月，美国食品药品监督管理局（FDA）授予托沙妥昔单抗（AR-301）“合格传染病产品”（QIDP）资格，以支持其作为辅助治疗药物的加速临床开发Staphylococcus aureus 金黄色葡萄球菌pneumonia. 肺炎Top-line results from the first of two planned global Phase III studies assessing a single dose of AR-301 alongside standard-of-care antibiotics for ventilator-associated pneumonia (VAP) caused by 评估单剂量AR-301联合标准护理抗生素治疗由以下原因引起的呼吸机相关性肺炎（VAP）的两项计划全球III期研究中第一项研究的初步结果Staphylococcus aureus 金黄色葡萄球菌were announced in September 2023. The therapy demonstrated a favorable safety profile in the full analysis set (FAS). In the microbiologically confirmed subgroup, an 11.3% numerical increase in clinical cure rate at Day 21 was observed; however, this improvement did not achieve statistical significance.. 于2023年9月公布。该疗法在全分析集（FAS）中显示出良好的安全性特征。在微生物学确认的亚组中，第21天的临床治愈率数值上提高了11.3%；然而，这一改善未达到统计学显著性。Aptarion Biotech's AON-D21 Aptarion Biotech 公司的 AON-D21is an investigational L-aptamer, a synthetic nucleic acid–based therapeutic, designed to selectively block complement factor C5a, an important inflammatory mediator involved in excessive immune activation. Overactivation of C5a can drive severe inflammation, multi-organ dysfunction, and increased mortality. 是一种在研的L-适配体，一种基于合成核酸的治疗药物，旨在选择性阻断补体因子C5a，这是一种参与过度免疫激活的重要炎症介质。C5a的过度激活可导致严重炎症、多器官功能障碍以及死亡率升高。Preclinical studies have shown that AON-D21 is effective in translational models of pneumonia and sepsis, and it has also demonstrated potential in lung cancer, particularly when combined with immune checkpoint inhibitors, suggesting that modulation of C5a may have broad therapeutic applications across immune-driven diseases.. 临床前研究表明，AON-D21在肺炎和脓毒症的转化模型中有效，并且在肺癌中也显示出潜力，尤其是在与免疫检查点抑制剂联合使用时，这表明调节C5a可能在免疫驱动的疾病中具有广泛的治疗应用。The anticipated launch of these emerging therapies are poised to transform the pneumonia market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the pneumonia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.. 这些新兴疗法的预期上市将在未来几年重塑肺炎市场格局。随着这些前沿疗法不断成熟并获得监管批准，预计将改变肺炎市场的现状，提供新的护理标准，并为医疗创新和经济增长带来新机遇。Discover more about new antibiotics for pneumonia in development @ 了解更多关于正在研发中的新型肺炎抗生素信息 @Pneumonia Drugs 肺炎药物Recent Developments in the Pneumonia Market 肺炎市场的最新发展In 在March 2026, BioVersys 2026年3月，BioVersysannounced that the FDA had given the go-ahead for enrolling patients in the United States for the global Phase 3 RIV-TARGET clinical trial (NCT07326540). 宣布美国食品药品监督管理局（FDA）已批准在全球III期RIV-TARGET临床试验（NCT07326540）中纳入美国患者。In 在January 2026, 2026年1月，AON-D21 completed patient enrollment in the international Phase II ADCAP trial assessing its efficacy and safety in patients with severe community-acquired pneumonia. AON-D21已完成国际II期ADCAP试验的患者入组，该试验旨在评估其在重症社区获得性肺炎患者中的有效性和安全性。In 在March 2025, 2025年3月，AON-D21 received clearance of its US Investigational New Drug (IND) application, along with approval to expand the ongoing Phase II ADCAP trial to enroll up to 150 patients. AON-D21 的美国新药临床试验申请（IND）已获得批准，同时获准将正在进行的 ADCAP II 期临床试验的入组患者人数扩大至最多 150 名。What is Pneumonia? 什么是肺炎？Pneumonia is a respiratory infection that affects the lungs, specifically the tiny air sacs known as alveoli. In people with pneumonia, these air sacs become inflamed and may fill with fluid or pus, making it difficult for oxygen to pass into the bloodstream. This condition can be caused by bacteria, viruses, or fungi and may range from mild to severe, particularly in young children, older adults, and individuals with weakened immune systems. 肺炎是一种影响肺部的呼吸道感染，尤其累及被称为肺泡的微小气囊。在肺炎患者中，这些肺泡会发生炎症，并可能充满液体或脓液，从而阻碍氧气进入血液。该病可由细菌、病毒或真菌引起，病情轻重不一，在幼儿、老年人以及免疫系统较弱的人群中尤为严重。Common symptoms include cough, fever, chills, chest pain, shortness of breath, and fatigue. Pneumonia can be acquired in the community, hospitals, or healthcare settings, and timely diagnosis and treatment, such as antibiotics for bacterial infections or supportive care, are important to prevent complications and improve recovery.. 常见症状包括咳嗽、发热、寒战、胸痛、呼吸急促和疲劳。肺炎可能在社区、医院或医疗机构中感染，及时诊断和治疗（如针对细菌感染的抗生素治疗或支持性护理）对于预防并发症和促进康复至关重要。Pneumonia Epidemiology Segmentation 肺炎流行病学细分The pneumonia epidemiology section provides insights into the historical and current pneumonia patient pool and forecasted trends for the leading markets. Hospital-acquired pneumonia is associated with a significant risk of mortality, with ventilator-associated pneumonia reporting all-cause mortality rates of . 肺炎流行病学部分提供了对主要市场历史及当前肺炎患者群体和预测趋势的见解。医院获得性肺炎与显著的死亡风险相关，其中呼吸机相关性肺炎的全因死亡率报告为。20–50% 20–50%. 。The pneumonia treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into: 肺炎治疗市场报告提供了2022年至2036年研究期间主要市场的流行病学分析，细分如下：Total Incident Cases of Pneumonia 肺炎总病例数Clinical Subtype-specific Incident Cases of Pneumonia 肺炎的临床亚型特异性新发病例Etiology-specific Incident Cases of Pneumonia 按病因分类的肺炎新发病例Treated Cases of Pneumonia 肺炎治疗病例Pneumonia Market Report Metrics 肺炎市场报告指标Details 详情Study Period 学习周期2022–2036 2022–2036Coverage 覆盖范围7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 7国集团[美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本]。Pneumonia Epidemiology Segmentation 肺炎流行病学细分Total Incident Cases of Pneumonia, Clinical Subtype-specific Incident Cases of Pneumonia, Etiology-specific Incident Cases of Pneumonia, and Treated Cases of Pneumonia 肺炎总发病病例数、临床亚型特异性肺炎发病病例数、病因特异性肺炎发病病例数以及肺炎治疗病例数Key Pneumonia Companies 主要肺炎企业Aridis Pharmaceuticals, Aptarion Biotech, Biotest AG, Vaxcyte, Inc., CanSinoBIO, Inventprise, BioVersys, Basilea Pharmaceutica, Innoviva Specialty Therapeutics, and others Aridis Pharmaceuticals、Aptarion Biotech、Biotest AG、Vaxcyte, Inc.、康希诺生物、Inventprise、BioVersys、Basilea Pharmaceutica、Innoviva Specialty Therapeutics 等Key Pneumonia Therapies 关键肺炎疗法Tosatoxumab (AR-301), AON-D21, Trimodulin (BT588), VAX-24, VAX-31, PCV24, IVT PCV-25, BV100, ZEVTERA, XACDURO, and others 托萨妥珠单抗（AR-301）、AON-D21、曲莫杜林（BT588）、VAX-24、VAX-31、PCV24、IVT PCV-25、BV100、ZEVTERA、XACDURO 等Scope of the 的范围Pneumonia 肺炎Market Report 市场报告Therapeutic Assessment: 治疗性评估：Pneumonia current marketed and emerging therapies 肺炎的现有上市疗法及新兴疗法Pneumonia 肺炎Market Dynamics: 市场动态：Key Market Forecast Assumptions of Emerging Pneumonia Drugs and Market Outlook 新兴肺炎药物的关键市场预测假设及市场前景Competitive Intelligence Analysis: 竞争情报分析：SWOT analysis and Market entry strategies SWOT分析与市场进入策略Unmet Needs, KOL's views, Analyst's views, Pneumonia Market Access and Reimbursement 未满足的需求、关键意见领袖的观点、分析师的观点、肺炎市场准入与报销Download the report to understand which region dominates pneumonia therapeutics market @ 下载报告以了解哪个地区在肺炎治疗市场占据主导地位 @Pneumonia Market Analysis 肺炎市场分析Table of Contents 目录1 1Pneumonia Market Key Insights 肺炎市场关键洞察2 2Pneumonia Market Report Introduction 肺炎市场报告简介3 3Pneumonia Market Overview at a Glance 肺炎市场概览3.1 3.1Market Share (%) Distribution of Pneumonia by Therapies in the 7MM in 2025 2025年七大主要市场（7MM）按治疗方案划分的肺炎市场份额（%）分布3.2 3.2Market Share (%) Distribution of Pneumonia by Therapies in the 7MM in 2036 2036年七国市场（7MM）肺炎治疗药物市场份额（%）分布4 4Methodology 方法论5 5Executive Summary 执行摘要6 6Key Events 关键事件7 7Disease Background and Overview: Pneumonia 疾病背景与概述：肺炎7.1 7.1Introduction 简介7.2 7.2Classification 分类7.3 7.3Causes 原因7.4 7.4Signs and Symptoms 体征与症状7.5 7.5Pathophysiology 病理生理学7.6 7.6Clinical features 临床特征7.7 7.7Diagnosis 诊断7.8 7.8Treatment and Management 治疗与管理8 8Epidemiology and Patient Population of Pneumonia in the 7MM 七大主要市场肺炎的流行病学与患者人群8.1 8.1Key Findings 主要发现8.2 8.2Assumptions and Rationale 假设与理由8.3 8.3Total Incident Cases of Pneumonia in the 7MM 七国市场（7MM）肺炎总发病病例数8.4 8.4The US 美国8.4.1 8.4.1Total Incident Cases of Pneumonia 肺炎总发病病例数8.4.2 8.4.2Clinical subtype-specific Incident Cases of Pneumonia 肺炎的临床亚型特异性新发病例8.4.3 8.4.3Etiology-specific Incident Cases of Pneumonia 按病因分类的肺炎新发病例8.4.4 8.4.4Treated Cases of Pneumonia 肺炎治疗病例8.5 8.5EU4 and the UK 欧盟四国与英国8.6 8.6Japan 日本9 9Pneumonia Patient Journey 肺炎患者就诊历程10 十Marketed Pneumonia Therapies 已上市的肺炎治疗药物10.1 10.1Key Cross Competition 关键交叉竞争10.2 10.2ZEVTERA (ceftobiprole medocaril sodium): Basilea Pharmaceutica/ Innoviva Specialty Therapeutics ZEVTERA（头孢比普罗酯甲氧基钠）：Basilea Pharmaceutica/Innoviva Specialty Therapeutics10.2.1 10.2.1Product Description 产品描述10.2.2 10.2.2Regulatory Milestone 监管里程碑10.2.3 10.2.3Other Developmental Activities 其他发展性活动10.2.4 10.2.4Clinical Trials Information 临床试验信息10.2.5 10.2.5Safety and Efficacy 安全性和有效性10.2.6 10.2.6Analyst Views 分析师观点10.3 10.3XACDURO (sulbactam + durlobactam): Innoviva Specialty Therapeutics XACDURO（舒巴坦 + 杜洛巴坦）：Innoviva Specialty TherapeuticsList to be continued in the final report. 清单将在最终报告中继续列出。11 十一Emerging Pneumonia Therapies 新兴肺炎疗法11.1 11.1Key Cross Competition 关键交叉竞赛11.2 11.2Tosatoxumab (AR-301): Aridis Pharmaceuticals 托萨妥昔单抗（AR-301）：Aridis Pharmaceuticals11.2.1 11.2.1Drug Description 药物说明11.2.2 11.2.2Other Developmental Activities 其他发展活动11.2.3 11.2.3Clinical Trials Information 临床试验信息11.2.4 11.2.4Safety and Efficacy 安全性与有效性11.2.5 11.2.5Analyst Views 分析师观点11.3 11.3AON-D21: Aptarion Biotech AON-D21：阿普塔里昂生物技术公司List to be continued in the final report. 清单将在最终报告中继续列出。12 12Pneumonia: Market Analysis 肺炎：市场分析12.1 12.1Key Findings 主要发现12.2 12.2Key Pneumonia Market Forecast Assumptions 关键肺炎市场预测假设12.3 12.3Pneumonia Market Outlook 肺炎市场前景12.4 12.4Conjoint Analysis 联合分析12.5 12.5Total Market Size of Pneumonia in the 7MM 七国市场（7MM）肺炎总市场规模12.6 12.6Market Size of Pneumonia by Therapies in the 7MM 七大主要市场中按疗法划分的肺炎市场规模12.7 12.7The US Pneumonia Market 美国肺炎市场12.8.1 12.8.1Total Market Size of Pneumonia 肺炎市场总规模12.8 12.8EU4 and the UK Pneumonia Market 欧盟四国与英国肺炎市场12.9 12.9Japan Pneumonia Market 日本肺炎市场13 13Key Opinion Leaders' Views on Pneumonia 关键意见领袖对肺炎的看法14 十四Pneumonia Market SWOT Analysis 肺炎市场SWOT分析15 15Pneumonia Market Unmet Needs 肺炎市场未满足的需求16 十六Pneumonia Market Access and Reimbursement 肺炎市场准入与报销16.1 16.1The US 美国16.2 16.2In EU4 and the UK 在欧盟和英国16.3 16.3Japan 日本17 17Acronyms and Abbreviations 缩略语和缩写18 十八Bibliography 参考文献19 十九Pneumonia Market Report Methodology 肺炎市场报告方法论Related Reports 相关报告Pneumonia, Pneumococcal Clinical Trial Analysis 肺炎链球菌性肺炎临床试验分析Pneumonia, Pneumococcal Pipeline Insight 肺炎链球菌性肺炎研发管线洞察– –2026 2026report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pneumonia, pneumococcal companies, including 报告提供了关于管线格局、管线药物概况（包括临床和非临床阶段产品）以及关键肺炎和肺炎球菌公司的全面见解，包括Biotest AG, Vaxcyte, Inc., Eubiologics Ltd., Eagle Pharmaceuticals, GlaxoSmithKline Biotest AG、Vaxcyte, Inc.、Eubiologics Ltd.、Eagle Pharmaceuticals、葛兰素史克, ，among others. 其中包括。Community-acquired Bacterial Pneumonia Market 社区获得性细菌性肺炎市场Community-acquired Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast – 2034 社区获得性细菌性肺炎市场洞察、流行病学及市场预测（至2034年）report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CABP companies including 报告提供对疾病的深入理解、历史和预测的流行病学，以及市场趋势、市场驱动因素、市场障碍和关键CABP公司，包括Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical, Forest Pharmaceuticals, Pfizer, Paratek Pharmaceuticals, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Merck Sharp & Dohme Inc., Cubist Pharmaceuticals LLC, Shionogi Inc., Allergan, Eagle Pharmaceutical Inc., Combioxin SA, Takeda, TiGenix,. 纳布里瓦治疗公司、美林塔治疗公司、若杉制药、森林制药、辉瑞、帕拉特克制药、坎伯兰制药公司、泰万斯生物制药、默沙东公司、库比斯特制药有限责任公司、盐野义公司、艾尔建、伊戈尔制药公司、Combioxin SA、武田制药、TiGenix。and others. 等等。Hospital-acquired and Ventilator-associated Bacterial Pneumonia 医院获得性肺炎和呼吸机相关性细菌性肺炎Market 市场Hospital-acquired and Ventilator-associated Bacterial Pneumonia 医院获得性及呼吸机相关性细菌性肺炎Market Insights, Epidemiology, and Market Forecast 市场洞察、流行病学及市场预测– –2034 2034report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HABP/VABP companies including 本报告深入解析了疾病状况、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和关键的HABP/VABP企业，包括Basilea, Merck, Shionogi, Pfizer, Aridis Pharmaceuticals, Polyphor, Aerucin, Motif Bio 巴塞尔制药、默克、盐野义、辉瑞、Aridis Pharmaceuticals、Polyphor、Aerucin、Motif Bio, ，and others. 以及其他。Bacterial Pneumonia 细菌性肺炎Market 市场Bacterial Pneumonia 细菌性肺炎Market Insights, Epidemiology, and Market Forecast 市场洞察、流行病学及市场预测– –2034 2034report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bacterial pneumonia companies including 本报告深入解析了该疾病、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和主要的细菌性肺炎企业，包括Pfizer, Forecast Laboratories, Melinta Therapeutics Inc., Merck Sharp & Dohme LLC, Melinta Therapeutics Inc., Evopoint Biosciences Inc., Paratek Pharmaceuticals Inc., Wockhardt, Clarametyx Biosciences Inc., AstraZeneca, Cumberland Pharmaceuticals, Eagle Pharmaceuticals Inc., Bayer 辉瑞公司、Forecast Laboratories、Melinta Therapeutics Inc.、默沙东有限责任公司、Melinta Therapeutics Inc.、Evopoint Biosciences Inc.、Paratek Pharmaceuticals Inc.、Wockhardt、Clarametyx Biosciences Inc.、阿斯利康、Cumberland Pharmaceuticals、Eagle Pharmaceuticals Inc.、拜耳, ，and others. 等等。About 关于DelveInsight DelveInsightDelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve. DelveInsight 是一家领先的商业咨询和市场研究公司，专注于生命科学领域。它通过提供全面的端到端解决方案来帮助制药公司提升业绩。通过我们基于订阅的平台 PharmDelve，您可以轻松获取所有医疗保健和制药市场研究报告。. 。Contact Us 联系我们Shruti Thakur 什鲁蒂·塔库尔[emailprotected] [email protected]+14699457679 +14699457679www.delveinsight.com www.delveinsight.comLogo: 标志：https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpgSOURCE DelveInsight Business Research, LLP 来源：DelveInsight Business Research, LLP21 二十一% %more press release views with 更多新闻稿浏览量，通过Request a Demo 请求演示

First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus Two-Stage, Dose-Escalation Study Designed with Primary Objective to Evaluate Safety and Tolerability and Secondary Objective to Assess Antigen-Specific Immune Responses Group A Strep Is Responsible for Approximately 800 Million New Cases of Illness and More Than 600,000 Deaths Annually Worldwide, with No Approved Vaccine and Significant Public Health Burden SAN CARLOS, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from bacterial diseases, today announced that the first participant was dosed in the Phase 1, first-in-human study evaluating VAX-A1, the Company’s investigational prophylactic vaccine candidate for the prevention of disease caused by Group A Streptococcus (Group A Strep), in healthy adults aged 18 to 40 years. The Company expects to announce topline data from the study in the second half of 2027. The primary objective of this randomized, double-blind, placebo-controlled, dose-escalation, two-stage study is assessing the safety and tolerability of VAX-A1, along with a secondary objective of evaluating initial immunogenicity data, to support potential further advancement. The Stage 1 portion of the study is evaluating three dose levels (Low, Mid and High) compared to placebo in approximately 12 adults in a controlled, staged enrollment and dose-escalation approach. Following completion of the Stage 1 Month 1 visit, an independent Data Safety Monitoring Board (DSMB) will review unblinded safety and tolerability data. Upon DSMB approval, the Stage 2 portion of the study is expected to proceed and evaluate the same three dose levels compared to placebo in approximately 68 adults. All participants in the study will be evaluated for safety through six months following the second dose. “Initiation of our VAX-A1 adult study represents an important milestone as we advance a novel approach to addressing disease caused by Group A Strep, a significant global public health challenge with no approved vaccine,” said Grant Pickering, Chief Executive Officer and Co-Founder of Vaxcyte. “VAX-A1 is designed to leverage our platform to target conserved elements of the pathogen and disarm its defense mechanisms to provide broad protective immune responses across Group A Strep subtypes. We believe this program has the potential to advance a meaningful preventative approach and look forward to generating initial clinical data to provide a foundation for evaluating next steps in the development of VAX-A1.” “Group A Strep is responsible for a wide spectrum of disease ranging from strep throat to severe invasive infections and immune-mediated conditions such as acute rheumatic fever, rheumatic heart disease and post-streptococcal glomerulonephritis,” said Jim Wassil, Executive Vice President and Chief Operating Officer of Vaxcyte. “The burden of disease affects both adults and children globally and contributes to substantial healthcare costs and antibiotic use. In the U.S., serious Group A Strep infections have risen over the past decade and reached a 20-year high in 2023, while antibiotic resistance has also increased, reinforcing the need for preventative approaches such as vaccination to help improve outcomes.” About the VAX-A1 Adult Phase 1 Study This randomized, double-blind, placebo-controlled, two-stage, dose-escalation clinical study is evaluating VAX-A1 in approximately 80 healthy adults aged 18 to 40 years. Additional information about the study can be found at under the identifier NCT07616934 . Stage 1 of the study will enroll approximately 12 participants to evaluate VAX-A1 at three dose levels (Low, Mid and High), in a controlled, staged enrollment and dose-escalation approach. Dose escalation for each cohort in Stage 1 will be based on a review of blinded safety and tolerability data by the Company’s Internal Safety Team prior to proceeding with enrolling the next cohort. Following completion of the Stage 1 Month 1 visit, an independent DSMB will review unblinded safety and tolerability data. Upon DSMB approval, Stage 2 is expected to proceed and enroll approximately 68 participants to further evaluate VAX-A1 across the same three dose levels. The study is being conducted at an investigative site in Australia, where Group A Strep has been especially problematic and where there are experienced investigator networks with expertise in Group A Strep. Participant Overview Stage 1 (n=12): Participants will be randomized 3:1 to receive VAX-A1 or placebo across three dose levels (Low, Mid and High). Stage 2 (n=68): Participants will be randomized 1:1:1:1 to receive VAX-A1 at one of the three dose levels or placebo. All participants are expected to receive two doses administered approximately two months apart. Safety and Immunogenicity Assessments Primary objectives include evaluation of safety and tolerability, including assessment of solicited and unsolicited adverse events, serious adverse events and adverse events of special interest. Secondary objectives include evaluation of antigen-specific immune responses to Group A Strep antigens, including serum immunoglobulin G (IgG) responses to C5a peptidase (ScpA), streptolysin O (SLO), S. pyogenes adhesion and division protein (SpyAD) and a universal polysaccharide (modified Group A carbohydrate or GAC PR ). Safety and tolerability will be assessed for approximately six months following the second and final vaccination. About Group A Strep Group A Strep is one of the leading causes of bacterial infections worldwide, responsible for a broad spectrum of disease ranging from common illnesses such as strep throat and skin infections to severe invasive disease, including necrotizing fasciitis and streptococcal toxic shock syndrome, as well as immune-mediated sequelae such as acute rheumatic fever, rheumatic heart disease and post-streptococcal glomerulonephritis, a form of kidney inflammation. With an estimated 800 million new cases of illness and more than 600,000 deaths annually worldwide, Group A Strep remains a major clinical burden. The economic impact is substantial, exceeding an estimated $6 billion annually in the U.S. alone. The public health challenge associated with Group A Strep is compounded by evolving epidemiology, including increasing rates of invasive disease and the re-emergence of certain manifestations in markets with historically lower disease burden. Group A Strep also drives significant antibiotic use, especially among children, contributing to rising resistance to multiple antibiotic classes. As a result, Group A Strep contributes to the global threat of antimicrobial resistance (AMR), reinforcing the need for preventative approaches such as vaccination. About VAX-A1 VAX-A1 is a prophylactic vaccine candidate designed to provide broad protection against Group A Strep by targeting conserved antigens associated with immune evasion and virulence. The candidate incorporates three protein antigens, including C5a peptidase (ScpA), streptolysin O (SLO) and S. pyogenes adhesion and division protein (SpyAD), as well as a modified Group A carbohydrate (GAC PR ) designed to remove potentially cross-reactive epitopes historically associated with autoimmune complications. VAX-A1 is being developed using Vaxcyte’s cell-free protein synthesis platform, which enables precise antigen design and site-specific conjugation intended to preserve immunogenicity while avoiding problematic regions. The vaccine is designed to induce functional immune responses against conserved structures of the pathogen and disarm its defense mechanisms, providing broad, strain-independent protection. This approach is intended to address limitations of prior vaccine strategies, including antigen variability and concerns regarding autoimmune cross-reactivity. About Vaxcyte Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent PCV candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of IPD and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise. VAX-A1 is a prophylactic vaccine candidate designed to provide broad, strain-independent protection against disease caused by Group A Strep and is currently being evaluated in a Phase 1 clinical study in adults. Group A Strep remains a significant global cause of morbidity and mortality across both adult and pediatric populations and is a leading driver of antibiotic use, underscoring the substantial public health burden. Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF ® , its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-GI, a vaccine candidate designed to prevent Shigella. For more information, visit . Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the potential benefits of Vaxcyte’s carrier-sparing platform and vaccine candidates, including, but not limited to, breadth of coverage, the ability to deliver potentially best-in-class vaccines, the ability to improve upon the standard-of-care, and the ability to significantly reduce the burden of disease; the expected timing of the announcement of topline data from the VAX-A1 Phase 1 study; the demand for Vaxcyte’s vaccine candidates; and other statements that are not historical fact. The words “anticipate,” “believe,” “could,” “expect,” “intend,” “may,” “on track,” “potential,” “should,” “would” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on Vaxcyte’s current expectations and actual results and timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, including, without limitation, risks related to Vaxcyte’s product development programs, including development timelines, success and timing of chemistry, manufacturing and controls and related manufacturing activities, potential delays or inability to obtain and maintain required regulatory approvals for its vaccine candidates, and the risks and uncertainties inherent with preclinical and clinical development processes; the success, cost and timing of all development activities and clinical trials; and sufficiency of cash and other funding to support Vaxcyte’s development programs and other operating expenses. These and other risks are described more fully in Vaxcyte’s filings with the Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q filed with the SEC on May 6, 2026, or in other documents Vaxcyte subsequently files with or furnishes to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date, and readers should not rely upon the information in this press release as current or accurate after its publication date. Vaxcyte undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations. Contacts: Patrick Ryan, Executive Director, Corporate Affairs Vaxcyte, Inc. 415-606-5135 media@vaxcyte.com Jeff Macdonald, Executive Director, Investor Relations Vaxcyte, Inc. 917-371-0940 investors@vaxcyte.com